Short answer: FDA treated a China-manufactured aloe vera gel as an unapproved drug because its label and website promoted uses involving sunburn, antiseptic action, acne control, irritated skin, and insect bites. In US law, intended use — shown by claims and context — can move a personal-care product from cosmetics rules into drug rules.
This article summarizes a public FDA import-alert entry. The manufacturer named in that record is not identified as an FDABridge client.
What did the FDA import alert say?
FDA Import Alert 66-41 lists Aloe Vera Gel marketed as Republic Cosmetics and manufactured by Guangzhou Biying Cosmetics Co., Ltd. in China. The entry, published April 12, 2022, states that label and website claims included sunburn, antiseptic, acne control, irritated skin, and insect-bite uses. FDA described the product as appearing to be an unapproved new drug.
The alert is a practical example of FDA reviewing more than the ingredient deck. Aloe vera can be used in an ordinary moisturizing cosmetic, but the same formula can acquire a drug intended use when marketing promises to treat or prevent a condition or affect the structure or function of the body.
Which cosmetic claims are most likely to trigger drug classification?
Claims involving acne treatment, eczema, psoriasis, wound healing, infection, inflammation, pain, hair regrowth, antiseptic action, sunburn treatment, or prevention of disease deserve immediate regulatory review. The exact wording, product presentation, active ingredients, directions, consumer understanding, testimonials, and linked web content can all contribute to intended use.
A disclaimer saying 'not intended to diagnose, treat, cure, or prevent disease' does not neutralize explicit treatment claims elsewhere. Likewise, registering a cosmetic facility under MoCRA and listing the product in Cosmetics Direct do not authorize drug claims.
Why websites and retailer listings matter
FDA's public entry refers to both the product label and website. Exporters should therefore review every US-facing claim surface: primary and secondary packaging, product pages, Amazon listings, distributor catalogs, paid advertisements, social-media posts, influencer briefs, before-and-after images, and customer testimonials reused by the brand.
A compliant label paired with a noncompliant product page still creates regulatory exposure. For international brands, the common failure is translating domestic-market therapeutic language directly into English without reassessing US product classification.
A prelaunch claims-control checklist
- Create one master inventory of every express and implied claim used in US commerce.
- Classify each SKU before filing: cosmetic, OTC drug, prescription drug, device, or combination product.
- Separate appearance and cleansing claims from claims about disease, healing, body structure, or physiological function.
- Require regulatory approval before distributors, marketplaces, or influencers publish new claims.
- Recheck claims whenever the formula, label, campaign, target consumer, or sales channel changes.
Quick answers for beauty brands
Is aloe vera gel automatically a drug in the United States?
No. Classification depends on intended use. A basic moisturizing or soothing cosmetic claim is different from a claim to treat sunburn, acne, infection, or insect bites.
Can MoCRA product listing make therapeutic claims legal?
No. MoCRA filings apply to cosmetics. A product marketed with drug intended uses must follow the applicable drug pathway and cannot rely on cosmetic registration or listing.
Verified public source
- FDA Import Alert 66-41, including the Guangzhou Biying Cosmetics aloe vera gel entry: https://www.accessdata.fda.gov/cms_ia/importalert_190.html
FDABridge reviews cosmetic classification, MoCRA filings, ingredient decks, labels, and US-facing claims before launch. Visit fdabridge.com/cosmetics or fdabridge.com/contact.
ایسا آپ کے ساتھ نہ ہونے دیں
ہر FDA کہانی ایک حقیقی تعمیل کا معاملہ ہے۔ ہماری خدمات دیکھیں۔